EJNMMI Research

SJR Rank #6,164H-index: 62SJR: 0.862Best quartile: Q1Open AccessAPC: US$3,190Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Springer Science and Business Media Deutschland GmbH

Country

Germany

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Radiology, Nuclear Medicine and ImagingQ1

Areas: Medicine

Most published research topics

Medical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchRadiomics and Machine Learning in Medical ImagingNeuroendocrine Tumor Research AdvancesPeptidase Inhibition and AnalysisCardiac Imaging and DiagnosticsAdvanced MRI Techniques and ApplicationsGlioma Diagnosis and TreatmentProstate Cancer Diagnosis and Treatment

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs080160240320

Documents per Year

2022202504080120160

Detailed Information

ISSN

2191-219X

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

2.90

References per Document

34.76

Coverage

2011-2026

Scope

EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.

Metrics from SCImago Journal Rank 2025. View on SCImago